Objective: Tigecycline has a wide spectrum antimicrobial activity including multi-drug resistant and extended drug resistant nosocomial Gram-negative bacteria. Although its pediatric use has not been approved, clinicians are sometimes obligated to choose tigecycline as salvage therapy. In this study, we present our clinical experience regarding tigecycline use in children. Material and Methods: This was a retrospective study of children who had been given tigecycline therapy at least 48 consecutive hours of duration in the pediatric departments of two tertiary-centers from January 2011 to March 2016. Results: Twenty four patients (13 female, 54.2%) with median age of 96 months (1-192) were enrolled. Tigecycline was started for ventilator associated pneumonia (n= 10, 41.7%), blood stream infection (n= 7, 29.2%), catheter related infection (n= 1, 4.2%), complicated skin soft tissue intection (n= 1, 4.2%) and emprically (n= 5, 20.8%). The most common isolated pathogen was Acinetobacter baumannii (n= 13, 54.2%). Other pathogens were Klebsiella spp. (n= 4, 16.6%), methicilline resistant Staphylococcus aureus, (n= 1, 42%) and Leptospira spp. (n= 1, 4.2%). All of the patients had tigecycline combination therapy. The most common combination was tigecycline + colistin (n= 10, 41.7%). Two patients (8.3%) had mild adverse events. The mortality rate was 45.8%. There was negative correlation between the age of patients and mortality rate (p= 0.006). Conclusion: Tigecycline may be used in critically ill children as salvage therapy with considerably mild side effects.